Literature DB >> 26683465

A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts.

Ulrike Schueler1, Christine Kaneski2, Alan Remaley3, Stephen Demosky3, Nancy Dwyer4, Joan Blanchette-Mackie4, John Hanover4, Roscoe Brady2.   

Abstract

Fabry disease is an X-linked sphingolipid storage disorder caused by a deficiency of the lysosomal enzyme α-galactosidase A (AGA, EC 3.2.1.22) resulting in the intracellular accumulation of globotriaosylceramide (Gb3). We found that Gb3 storage also correlates with accumulation of endosomal-lysosomal cholesterol in Fabry fibroblasts. This cholesterol accumulation may contribute to the phenotypic pathology of Fabry disease by slowing endosomal-lysosomal trafficking. We found that LDL receptor expression is not downregulated in Fabry fibroblasts resulting in accumulation of both cholesterol and Gb3. 5A-Palmitoyl oleoyl-phosphatidylcholine (5AP) is a phospholipid complex containing a short synthetic peptide that mimics apolipoprotein A1, the main protein component of high-density lipoprotein (HDL) that mediates the efflux of cholesterol from cells via the ATP-binding cassette transporter. We used 5AP and HDL to remove cholesterol from Fabry fibroblasts to examine the fate of accumulated cellular Gb3. Using immunostaining techniques, we found that 5AP is highly effective for depleting cholesterol and Gb3 in these cells. 5AP restores the ApoA-1-mediated cholesterol efflux leading to mobilization of cholesterol and reduction of Gb3 in Fabry fibroblasts.

Entities:  

Year:  2015        PMID: 26683465      PMCID: PMC5059196          DOI: 10.1007/8904_2015_507

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  18 in total

1.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.

Authors:  Thomas P Mechtler; Susanne Stary; Thomas F Metz; Víctor R De Jesús; Susanne Greber-Platzer; Arnold Pollak; Kurt R Herkner; Berthold Streubel; David C Kasper
Journal:  Lancet       Date:  2011-11-29       Impact factor: 79.321

2.  Effect of selective LDL-apheresis in a Fabry patient with recurrent strokes.

Authors:  K Utsumi; T Seta; T Katsumata; Y Komaba; H Igarashi; K-I Katsura; Y Iino; Y Katayama
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

3.  Regulation of the activity of the low density lipoprotein receptor in human fibroblasts.

Authors:  M S Brown; J L Goldstein
Journal:  Cell       Date:  1975-11       Impact factor: 41.582

4.  5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Authors:  Marcelo J A Amar; Wilissa D'Souza; Scott Turner; Stephen Demosky; Denis Sviridov; John Stonik; Jayraz Luchoomun; Jason Voogt; Marc Hellerstein; Dmitri Sviridov; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2010-05-19       Impact factor: 4.030

5.  Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator.

Authors:  Elias N Glaros; Woojin Scott Kim; Carmel M Quinn; Jenny Wong; Ingrid Gelissen; Wendy Jessup; Brett Garner
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

6.  Glycosphingolipids and plasma lipoproteins: a review.

Authors:  S Chatterjee; P O Kwiterovich
Journal:  Can J Biochem Cell Biol       Date:  1984-06

7.  Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL.

Authors:  Z F Stephan; E C Yurachek
Journal:  J Lipid Res       Date:  1993-02       Impact factor: 5.922

Review 8.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

9.  The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease.

Authors:  Edward B Neufeld; John A Stonik; Stephen J Demosky; Catherine L Knapper; Christian A Combs; Adele Cooney; Marcella Comly; Nancy Dwyer; Joan Blanchette-Mackie; Alan T Remaley; Silvia Santamarina-Fojo; H Bryan Brewer
Journal:  J Biol Chem       Date:  2004-01-27       Impact factor: 5.157

Review 10.  Secondary lipid accumulation in lysosomal disease.

Authors:  Steven U Walkley; Marie T Vanier
Journal:  Biochim Biophys Acta       Date:  2008-12-09
View more
  4 in total

1.  Development of a model system for neuronal dysfunction in Fabry disease.

Authors:  Christine R Kaneski; Roscoe O Brady; John A Hanover; Ulrike H Schueler
Journal:  Mol Genet Metab       Date:  2016-07-22       Impact factor: 4.797

2.  Lipid profile in adult patients with Fabry disease - Ten-year follow up.

Authors:  Karolina M Stepien; Chris J Hendriksz
Journal:  Mol Genet Metab Rep       Date:  2017-07-13

3.  Generation of an in vitro model for peripheral neuropathy in Fabry disease using CRISPR-Cas9 in the nociceptive dorsal root ganglion cell line 50B11.

Authors:  Christine R Kaneski; John A Hanover; Ulrike H Schueler Hoffman
Journal:  Mol Genet Metab Rep       Date:  2022-04-27

Review 4.  Developments in the treatment of Fabry disease.

Authors:  Sanne J van der Veen; Carla E M Hollak; André B P van Kuilenburg; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2020-03-02       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.